2022 American Transplant Congress
External Validation of the Abbreviated Ibox Scoring System at One-Year Post Kidney Transplant as a Surrogate Endpoint for Death-Censored Graft Survival
*Purpose: The Transplant Therapeutics Consortium seeks to translate the iBox from Loupy et al., 2019 into a surrogate endpoint for five-year death-censored graft survival after…2022 American Transplant Congress
Low Fixed Tacrolimus Starting Dose and the Correlation with Renal Allograft Rejection
David Geffen School of Medicine, Los Angeles, CA
*Purpose: Achieving a tacrolimus therapeutic trough concentration (C0) by post-operative day (POD) 3-7 has been associated with a reduced risk for rejection. Although FDA prescribing…2022 American Transplant Congress
Impact of Early Calcineurin-Inhibitor Conversion to Belatacept on Renal Allograft Function in a Steroid-Free Maintenance Regimen: Results from a Randomized Controlled Study
*Purpose: Belatacept (Bela) was developed to minimize nephrotoxicity and cardiovascular risk associated with Calcineurin inhibitors (CNIs). Early steroid withdrawal (ESW) and simultaneous CNI avoidance (CNIA)…2022 American Transplant Congress
Covid-19 Vaccination Response In Tacrolimus Treated Kidney Transplant Recipients With And Without Mycophenolate Mofetil: Follow-up Of A Randomized Controlled Trial
*Purpose: To investigate the effect of mycophenolate mofetil (MMF) on SARS-CoV-2 vaccination response in kidney transplant recipients using the standard immunosuppressive regimen of tacrolimus (TAC)…2022 American Transplant Congress
A Single-Center’s Outcomes of Combined Heart-Liver Transplantation
*Purpose: The purpose of this study was to evaluate rejection outcomes in our combined heart-liver transplant (CHLT) recipients at 6 months.*Methods: This is a retrospective,…2022 American Transplant Congress
SARS-CoV-2 Antibody Response by mRNA Vaccine Platform in Incrementally Immunosuppressed Patients
1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: This study compares SARS-CoV-2 antibody responses between the two-dose mRNA-1273 and BNT162b2 vaccine series across groups of incrementally immunosuppressed patients.*Methods: Semiquantitative testing for antibodies…2022 American Transplant Congress
Understanding The Modification Of Eplet Mismatch Risk By Immunosuppression Regimen
*Purpose: Solid organ transplant donor-recipient eplet mismatch has been correlated with subsequent donor specific antibody (DSA) formation, antibody mediated rejection, and overall rejection rates. However,…2022 American Transplant Congress
Standard Induction with Basiliximab versus no Induction in Low Immunological Risk Kidney Transplant Recipients: Study Protocol for a Randomized Controlled Trial
1KFSHRC, RIYADH, Saudi Arabia, 2MOH, RIYADH, Saudi Arabia
*Purpose: To compare different induction therapeutic strategies with 2 doses of basiliximab vs. no induction in low immunologic risk kidney transplant recipients as per KFSHRC…2022 American Transplant Congress
Impact of Belatacept on Clinical Outcomes in Lung Transplant Patients with Antibody-Mediated Rejection
*Purpose: Antibody-mediated rejection (AMR) is cause of significant morbidity and mortality in lung transplant recipients (LTRs). An optimal therapeutic regimen is still lacking. Recent evidence…2022 American Transplant Congress
Induction of Tacrolimus Clearance by Steroids Varies by Cyp3a5 Genotype in Kidney Transplant Recipients: A Drug-Drug-Gene Interaction
*Purpose: Tacrolimus (TAC) is the primary immunosuppressant used in organ transplantation. TAC is a substrate for CYP3A4/5. These enzymes are inhibited or induced by multiple…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 138
- Next Page »
